Acadian Asset Management
PCVX icon

Acadian Asset Management’s Vaxcyte PCVX Stock Holding History

Acadian Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Sell
1,072
-5,223
-83% -$284K ﹤0.01% 1829
2025
Q4 		$289K Sell
6,295
-78,085
-93% -$3.49M ﹤0.01% 1440
2025
Q3 		$3.04M Buy
+84,380
New +$2.8M 0.01% 778
2024
Q4 		– Sell
-6,711
Closed -$766K – 2031
2024
Q3 		$766K Buy
+6,711
New +$605K ﹤0.01% 983

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's PCVX Position: Q1 2026 in Review

Acadian Asset Management reduced its Vaxcyte (PCVX) stake by 83% in Q1 2026, selling an estimated $284K and leaving 1,072 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Acadian Asset Management first reported a position in PCVX in Q3 2024 and has held it in 4 quarters since. The position peaked at $3.04M in Q3 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Acadian Asset Management held 1,072 shares of Vaxcyte worth $62K as of Q1 2026.
  • Acadian Asset Management sold 5,223 Vaxcyte shares in Q1 2026, an estimated $284K.
  • Vaxcyte made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1829 holding.
  • Acadian Asset Management first reported a position in Vaxcyte in Q3 2024 and has held it in 4 quarters since.
  • Acadian Asset Management's Vaxcyte position peaked at $3.04M in Q3 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.